EP 1812440 B1 20100922 - PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES
Title (en)
PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES
Title (de)
ALS INHIBITOREN VON PROTEINKINASEN GEEIGNETE PYRAZOLO[1,5-A]PYRIMIDINE
Title (fr)
PYRAZOLO[1,5-A]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE PROTEINES KINASES
Publication
Application
Priority
- US 2005040344 W 20051104
- US 62544604 P 20041104
Abstract (en)
[origin: WO2006052913A1] The present invention relates to compounds of formula (I) useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing the compounds of the invention.
IPC 8 full level
C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07D 231/00 (2006.01); C07D 239/00 (2006.01)
CPC (source: EP KR US)
A61K 31/519 (2013.01 - KR); A61P 1/00 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/18 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 17/08 (2017.12 - EP); A61P 17/10 (2017.12 - EP); A61P 17/14 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 21/04 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 27/16 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/04 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 37/08 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 487/04 (2013.01 - EP KR US); C07F 9/6561 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK YU
DOCDB simple family (publication)
WO 2006052913 A1 20060518; AT E482213 T1 20101015; AU 2005304784 A1 20060518; AU 2005304784 B2 20110324; CA 2586375 A1 20060518; CN 101094853 A 20071226; CN 101094853 B 20110713; DE 602005023763 D1 20101104; DK 1812440 T3 20110131; EP 1812440 A1 20070801; EP 1812440 B1 20100922; ES 2354824 T3 20110318; HK 1113569 A1 20081010; IL 182893 A0 20070819; JP 2008519059 A 20080605; JP 2009067803 A 20090402; JP 5030229 B2 20120919; KR 20070090172 A 20070905; MX 2007005439 A 20080219; MX 337817 B 20111104; NO 20072795 L 20070601; NZ 555236 A 20101029; PT 1812440 E 20110125; RU 2007120518 A 20081210; RU 2417996 C2 20110510; SI 1812440 T1 20110429; US 2006135537 A1 20060622; US 7528138 B2 20090505; ZA 200704476 B 20080925
DOCDB simple family (application)
US 2005040344 W 20051104; AT 05816516 T 20051104; AU 2005304784 A 20051104; CA 2586375 A 20051104; CN 200580045025 A 20051104; DE 602005023763 T 20051104; DK 05816516 T 20051104; EP 05816516 A 20051104; ES 05816516 T 20051104; HK 08102917 A 20080313; IL 18289307 A 20070501; JP 2007540144 A 20051104; JP 2008278235 A 20081029; KR 20077012308 A 20070531; MX 2007005439 A 20051104; NO 20072795 A 20070601; NZ 55523605 A 20051104; PT 05816516 T 20051104; RU 2007120518 A 20051104; SI 200531195 T 20051104; US 26693505 A 20051104; ZA 200704476 A 20051104